AUTHOR=Deng Min , Chai Huirong , Yang Meng , Wei Xueman , Zhang Wenjun , Wang Xuebin , Li Juanjuan , Wang Zhuo , Chen Haitao 

TITLE=Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review

JOURNAL=Frontiers in Oncology

VOLUME=11

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.736975

DOI=10.3389/fonc.2021.736975

ISSN=2234-943X

ABSTRACT=<sec><title>Objective</title><p>Enzalutamide is the most frequently prescribed compound for treating metastatic castration-resistant prostate cancer (mCRPC). Common adverse drug events of enzalutamide are febrile neutropenia, hot flashes, hypertension, and fatigue.</p></sec><sec><title>Methods</title><p>We present a case of a patient with mCRPC who received enzalutamide and developed Stevens-Johnson syndrome (SJS). The culprit drug was confirmed using the Naranjo Adverse Drug Reaction Probability Scale. Clinical characteristics and management principles were analyzed in combination with literature reports.</p></sec><sec><title>Results</title><p>SJS occurred within two weeks of enzalutamide therapy. Supportive care such as steroid treatment led to a complete resolution of skin lesions and improved clinical symptoms after three weeks.</p></sec><sec><title>Conclusion</title><p>Most cutaneous adverse events occur early during enzalutamide therapy, and close observation should be given within two weeks of starting treatment.</p></sec>